Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
Shoujie Huang(Xiamen University), Ningshao Xia(Xiamen University), Huirong Pan, Xingcheng Huang(Xiamen University), Chunlan Zhuang(Xiamen University), Xiaowen Hu(Xiamen University), Zhongze Wang(Beijing Fengtai Disease Prevention and Control Center), Wentong Shen, Changlin Yang, Xuefeng Zhang(Mississippi State University), Xia Zang, Kongxin Zhu(Xiamen University), Ying Dong(Xiamen University), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Zimin Tang(Xiamen University), Zizheng Zheng(Xiamen University), Xiaohui Liu(Xiamen University), Jun Zhang(Army Medical University), Yijun Wang(Guangzhou University of Chinese Medicine), Ting Wu(Xiamen University), Yingying Su(Xiamen University), Donglin Liu, Qi Chen(Wayne State University), Quan Tang, Han-Min Jiang, Yue Huang(Zhengzhou University), Huanhuan Cao, Shengxiang Ge(Xiamen University)
Cited by 70
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
|The Journal of Infectious Diseases|2020|391
Rat Hepatitis E Virus as Cause of Persistent Hepatitis after Liver Transplant
|Emerging infectious diseases|2018|268
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|Signal Transduction and Targeted Therapy|2021|204